Coxibs and cardiovascular disease

被引：680

作者：

FitzGerald, GA ^{[1
]}

机构：

[1] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 17期

关键词：

D O I：

10.1056/NEJMp048288

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1709 / 1711

页数：3

共 5 条

[1] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J].

Farkouh, ME ;

Kirshner, H ;

Harrington, RA ;

Ruland, S ;

Verheugt, FW ;

Schnitzer, T ;

Burmester, GR ;

Mysler, E ;

Hochberg, MC ;

Doherty, M ;

Ehrsam, E ;

Gitton, X ;

Krammer, G ;

Mellein, B ;

Gimona, A ;

Matchaba, P ;

Hawkey, CJ ;

Chesebro, JH .

LANCET, 2004, 364 (9435) :675-684

[2] COX-2 and beyond: Approaches to prostaglandin inhibition in human disease [J].

FitzGerald, G .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (11) :879-890

[3] Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2. [J].

FitzGerald, GA ;

Patrono, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :433-442

[4] COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease [J].

Ray, WA ;

Stein, CM ;

Daugherty, JR ;

Hall, K ;

Arbogast, PG ;

Griffin, MR .

LANCET, 2002, 360 (9339) :1071-1073

[5] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial [J].

Schnitzer, TJ ;